Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17185461)

  • 1. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
    Kashkar H; Deggerich A; Seeger JM; Yazdanpanah B; Wiegmann K; Haubert D; Pongratz C; Krönke M
    Blood; 2007 May; 109(9):3982-8. PubMed ID: 17185461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
    Celegato M; Borghese C; Casagrande N; Carbone A; Colombatti A; Aldinucci D
    Leuk Lymphoma; 2014 Jan; 55(1):149-59. PubMed ID: 23647062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
    Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
    Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
    Böll B; Hansen H; Heuck F; Reiners K; Borchmann P; Rothe A; Engert A; Pogge von Strandmann E
    Blood; 2005 Sep; 106(5):1839-42. PubMed ID: 15878978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells.
    Izban KF; Ergin M; Huang Q; Qin JZ; Martinez RL; Schnitzer B; Ni H; Nickoloff BJ; Alkan S
    Mod Pathol; 2001 Apr; 14(4):297-310. PubMed ID: 11301346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.
    Tao Y; Gao L; Wu X; Wang H; Yang G; Zhan F; Shi J
    PLoS One; 2013; 8(6):e67067. PubMed ID: 23826195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
    Zhao WL; Liu YY; Zhang QL; Wang L; Leboeuf C; Zhang YW; Ma J; Garcia JF; Song YP; Li JM; Shen ZX; Chen Z; Janin A; Chen SJ
    Blood; 2008 Apr; 111(7):3867-71. PubMed ID: 18235046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Liu CY; Shiau CW; Kuo HY; Huang HP; Chen MH; Tzeng CH; Chen KF
    Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
    Carter BZ; Mak DH; Wang Z; Ma W; Mak PY; Andreeff M; Davis RE
    Leuk Res; 2013 Aug; 37(8):974-9. PubMed ID: 23669290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
    Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.